<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>PROTAMINE SULFATE- protamine sulfate injection, solution </strong><br>Fresenius Kabi USA, LLC<br></p></div>
<h1>Protamine Sulfate Injection USP</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="a7dc690b-890c-4d75-a75e-a0f0cc204c71"></a><a name="section-1"></a><p></p>
<h1></h1>
<span class="Bold"><span class="Emphasis">For Intravenous Use</span></span><br>
</div>
<div class="Warning">
<a name="ad68844c-70f8-40e8-8f85-008b0d79c5b6"></a><a name="section-2"></a><p></p>
<h1>BOXED WARNING</h1>
<p class="First">Protamine sulfate can cause severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="443240" conceptname="Collapse">cardiovascular collapse</span>, noncardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>, catastrophic pulmonary <span class="product-label-link" type="condition" conceptid="4137788" conceptname="Vascular constriction">vasoconstriction</span>, and <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.  Risk factors include high dose or <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, rapid administration (see <span class="Bold"><span class="Emphasis"><a href="#a5ec87f0-2387-4502-b586-9c3962c0bfd0">WARNINGS</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#f78d07a1-8d64-4590-92bd-e59d80d60a65">DOSAGE AND ADMINISTRATION</a></span></span>), repeated doses, previous administration of protamine, and current or previous use of protamine-containing drugs (NPH insulin, protamine zinc insulin, and certain beta-blockers).  <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> to fish, previous vasectomy, and severe <span class="product-label-link" type="condition" conceptid="4047088" conceptname="Left ventricular systolic dysfunction">left ventricular dysfunction</span> and abnormal preoperative pulmonary hemodynamics also may be risk factors.  In patients with any of these risk factors, the risk to benefit of administration of protamine sulfate should be carefully considered.  Vasopressors and resuscitation equipment should be immediately available in case of a severe reaction to protamine.  Protamine sulfate should not be given when <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> occurs without prior heparin use.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="e6c6ec7f-9221-4bcd-9882-95914d330e91"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Protamines are simple proteins of low molecular weight that are rich in arginine and strongly basic.  They occur in the sperm of salmon and certain other species of fish.</p>
<p>Protamine sulfate occurs as fine white or off-white amorphous or crystalline powder.  It is sparingly soluble in water.  The pH is between 6.0 and 7.0.  The cationic hydrogenated protamine at a pH of 6.8 to 7.1 reacts with anionic heparin at a pH of 5.0 to 7.5 to form an inactive complex.</p>
<p>Protamine Sulfate Injection, USP is a sterile, isotonic solution of protamine sulfate.  It acts as a heparin antagonist.  It is also a weak anticoagulant.</p>
<p>Each mL contains: Protamine sulfate 10 mg; sodium chloride 9 mg; Water for Injection q.s.  Sulfuric acid and/or dibasic sodium phosphate (heptahydrate) may have been added for pH adjustment.</p>
<p>The preparation is preservative free.</p>
<p>Protamine sulfate is administered intravenously.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="c67a580e-7d1b-4604-b29f-42b04ffe8e18"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">When administered alone, protamine has an anticoagulant effect.  However, when it is given in the presence of heparin (which is strongly acidic), a stable salt is formed and the anticoagulant activity of both drugs is lost.</p>
<p>Protamine sulfate has a rapid onset of action.  Neutralization of heparin occurs within five minutes after intravenous administration of an appropriate dose of protamine sulfate.  Although the metabolic fate of the heparin-protamine complex has not been elucidated, it has been postulated that protamine sulfate in the heparin-protamine complex may be partially metabolized or may be attacked by fibrinolysin, thus freeing heparin.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="b7913e71-e8c4-4db4-b95f-b6d143403545"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Protamine Sulfate Injection, USP is indicated in the treatment of heparin overdosage.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="e82999c4-d13c-409a-be21-692a6520db7a"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Protamine sulfate is contraindicated in patients who have shown previous intolerance to the drug.</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="a5ec87f0-2387-4502-b586-9c3962c0bfd0"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Hyperheparinemia or <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> has been reported in experimental animals and in some patients 30 minutes to 18 hours after cardiac surgery (under cardiopulmonary bypass) in spite of complete neutralization of heparin by adequate doses of protamine sulfate at the end of the operation.  It is important to keep the patient under close observation after cardiac surgery.  Additional doses of protamine sulfate should be administered if indicated by coagulation studies, such as the heparin titration test with protamine and the determination of plasma <span class="product-label-link" type="condition" conceptid="4208541" conceptname="Thrombin time">thrombin time</span>.</p>
<p><span class="Bold"><span class="Emphasis">Too-rapid administration of protamine sulfate can cause severe hypotensive and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> </span></span>(see <span class="Bold"><span class="Emphasis"><a href="#f78d07a1-8d64-4590-92bd-e59d80d60a65"> DOSAGE AND ADMINISTRATION</a></span></span> and <span class="Bold"><span class="Emphasis"><a href="#a5ec87f0-2387-4502-b586-9c3962c0bfd0"> WARNINGS</a></span></span>).  Facilities to treat <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">shock</span> should be available.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="bde8da03-e933-4435-9b3a-7ceb93df22bb"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42232-9">
<a name="da85c28d-1ffa-47b6-bfdd-3fd062a2288b"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First"><span class="Bold"><span class="Emphasis">Because of the anticoagulant effect of protamine, it is unwise to give more than 50 mg over a short period unless a larger dose is clearly needed.</span></span></p>
<p>Patients with a history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> to fish may develop <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to protamine, although to date no relationship has been established between <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to protamine and <span class="product-label-link" type="condition" conceptid="4188027" conceptname="Food allergy">fish allergy</span>.</p>
<p>Previous exposure to protamine can induce a humoral immune response and predispose susceptible individuals to the development of untoward reactions from the subsequent use of this drug.  Patients exposed to protamine through the use of protamine-containing insulin or during heparin neutralization may experience life-threatening reactions and fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> upon receiving large doses of protamine intravenously.  Severe reactions to intravenous protamine can occur in the absence of local or <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> to subcutaneous injection of protamine-containing insulin.  Reports of the presence of antiprotamine antibodies in the sera of infertile or vasectomized men suggest that some of these individuals may react to the use of protamine sulfate.</p>
<p>Fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> has been reported in one patient with no prior history of allergies.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="f1978e9d-2425-411f-bd4c-5211540de44f"></a><a name="section-7.2"></a><p></p>
<h2>Drug Interactions<br>
</h2>
<p class="First">Protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins (see <span class="Bold"><span class="Emphasis"><a href="#f78d07a1-8d64-4590-92bd-e59d80d60a65"> DOSAGE AND ADMINISTRATION</a></span></span>).</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="d30211fe-c280-4a9c-8ae6-de50a71867e9"></a><a name="section-7.3"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility<br>
</h2>
<p class="First">Studies have not been performed to determine potential for carcinogenicity, mutagenicity or impairment of fertility.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b3869164-6aa1-4dbd-95e5-2f624c082ed2"></a><a name="section-7.4"></a><p></p>
<h2>Pregnancy</h2>
<p class="First"><span class="Italics"><span class="Emphasis">Pregnancy Category C</span></span>—Animal reproduction studies have not been conducted with protamine sulfate.  It is also not known whether protamine sulfate can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.  Protamine sulfate should be given to a pregnant woman only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="be3cd903-95de-4a54-9fb9-c664a434b89e"></a><a name="section-7.5"></a><p></p>
<h2>Nursing Mothers<br>
</h2>
<p class="First">It is not known whether this drug is excreted in human milk.  Because many drugs are excreted in human milk, caution should be exercised when protamine sulfate is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="b7a4c853-0685-4df8-8e9c-302e46f760e6"></a><a name="section-7.6"></a><p></p>
<h2>Pediatric Use<br>
</h2>
<p class="First">Safety and effectiveness in children have not been established.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="e00643c7-787d-4591-9ee8-ef0679867c52"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">The intravenous administration of protamine sulfate may cause a sudden <span class="product-label-link" type="condition" conceptid="314171" conceptname="Low blood pressure reading">fall in blood pressure</span> and <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>.  Other reactions include transitory <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> and <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">feeling of warmth</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">lassitude</span>.  <span class="product-label-link" type="condition" conceptid="134736" conceptname="Backache">Back pain</span> has been reported in conscious patients undergoing such procedures as cardiac catheterization.</p>
<p>Severe adverse reactions have been reported including: (1) <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> that resulted in severe <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, circulation collapse and capillary leak (see <span class="Bold"><span class="Emphasis"><a href="#bde8da03-e933-4435-9b3a-7ceb93df22bb"> PRECAUTIONS</a></span></span>).  Fatal <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> has been reported in one patient with no prior history of allergies; (2) <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">Anaphylactoid reactions</span> with <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span>, capillary leak, and noncardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span>; acute <span class="product-label-link" type="condition" conceptid="4322024" conceptname="Pulmonary hypertension">pulmonary hypertension</span>.</p>
<p>Complement activation by the heparin-protamine complexes, release of lysosomal enzymes from <span class="product-label-link" type="condition" conceptid="4148615" conceptname="Neutrophil count">neutrophils</span>, and prostaglandin and thomboxane generation have been associated with the development of <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span>.</p>
<p>Severe and potentially irreversible <span class="product-label-link" type="condition" conceptid="201965" conceptname="Shock">circulatory collapse</span> associated with myocardial failure and reduced <span class="product-label-link" type="condition" conceptid="4221102" conceptname="Cardiac output">cardiac output</span> can also occur.  The mechanism(s) of this reaction and the role played by concurrent factors are unclear.</p>
<p>High-protein, noncardiogenic <span class="product-label-link" type="condition" conceptid="4078925" conceptname="Pulmonary edema">pulmonary edema</span> associated with the use of protamine has been reported in patients on cardiopulmonary bypass who are undergoing cardiovascular surgery.  The etiologic role of protamine in the pathogenesis of this condition is uncertain, and multiple factors have been present in most cases.  The condition has been reported in association with administration of certain blood products, other drugs, cardiopulmonary bypass alone, and other etiologic factors.  It is difficult to treat, and it can be life-threatening.  Because fatal anaphylactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid reactions</span> have been reported after the administration of protamine sulfate, the drug should be given only when resuscitation techniques and treatment of anaphyactic and <span class="product-label-link" type="condition" conceptid="4148381" conceptname="Anaphylactoid reaction">anaphylactoid shock</span> are readily available.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="f4ab4f41-8fe5-479c-a9c9-886a174a41d6"></a><a name="section-9"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="34088-5">
<a name="d386ddb6-e9d0-48e2-937b-e9f6d1850a37"></a><a name="section-9.1"></a><p></p>
<h2>Signs and Symptoms<br>
</h2>
<p class="First"><span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">Overdose</span> of protamine sulfate may cause <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>.  Protamine has a weak anticoagulant effect due to an interaction with platelets and with many proteins including fibrinogen.  This effect should be distinguished from the rebound anticoagulation that may occur 30 minutes to 18 hours following the reversal of heparin with protamine.</p>
<p>Rapid administration of protamine is more likely to result in <span class="product-label-link" type="condition" conceptid="4169095" conceptname="Bradycardia">bradycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, a <span class="product-label-link" type="condition" conceptid="4141161" conceptname="Hot">sensation of warmth</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and severe <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>.  <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> has also occurred.</p>
<p>The median lethal dose of protamine sulfate is 50 mg/kg in mice.  Serum concentrations of protamine sulfate are not clinically useful.  Information is not available on the amount of drug in a single dose that is associated with overdosage or is likely to be life-threatening.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="ef468496-59ce-433f-b6a6-0df366e4a9c6"></a><a name="section-9.2"></a><p></p>
<h2>Treatment</h2>
<p class="First">To obtain up-to-date information about the treatment of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, a good resource is your certified Regional Poison Control Center.  Telephone numbers of certified poison control centers are listed in the <span class="Italics"><span class="Emphasis">Physicians’ Desk Reference (PDR</span></span>).  In managing overdosage, consider the possibility of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">multiple drug overdoses</span>, interaction among drugs and unusual drug kinetics in your patient.</p>
<p>Replace blood loss with blood transfusions or fresh frozen plasma.  </p>
<p>If the patient is hypotensive, consider fluids, epinephrine, dobutamine or dopamine.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="f78d07a1-8d64-4590-92bd-e59d80d60a65"></a><a name="section-10"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">Each mg of protamine sulfate, calculated on the dried basis, neutralizes not less than 100 USP Heparin Units.</p>
<p><span class="Bold"><span class="Emphasis">Protamine sulfate injection should be given by very slow intravenous injection over a 10-minute period in doses not to exceed 50 mg</span></span> (see <span class="Bold"><span class="Emphasis"><a href="#a5ec87f0-2387-4502-b586-9c3962c0bfd0"> WARNINGS</a></span></span>).</p>
<p>Protamine sulfate is intended for injection without further dilution; however, if further dilution is desired, D5-W or normal saline may be used.  Diluted solutions should not be stored since they contain no preservative.</p>
<p>Protamine sulfate should not be mixed with other drugs without knowledge of their compatibility, because protamine sulfate has been shown to be incompatible with certain antibiotics, including several of the cephalosporins and penicillins.</p>
<p>Because heparin disappears rapidly from the circulation, the dose of protamine sulfate required also decreases rapidly with the time elapsed following intravenous injection of heparin.  For example, if the protamine sulfate is administered 30 minutes after the heparin, one-half the usual dose may be sufficient.</p>
<p>The dosage of protamine sulfate should be guided by blood coagulation studies (see <span class="Bold"><span class="Emphasis"><a href="#a5ec87f0-2387-4502-b586-9c3962c0bfd0"> WARNINGS</a></span></span>).</p>
<p>Parenteral drug products should be visually inspected for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="e87ab89d-dfac-4355-a94d-f6d0278188df"></a><a name="section-11"></a><p></p>
<h1>HOW SUPPLIED</h1>
<table><tbody class="Headless">
<tr class="First">
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">Product</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top">
<p class="First"><span class="Bold"><span class="Emphasis">NDC</span></span></p>
<p><span class="Bold"><span class="Emphasis">No.</span></span></p>
</td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><br></td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">PRX22905  </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-229-94   </p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Protamine Sulfate Injection, USP, 50 mg (10 mg/mL, 5 mL) in a single dose flip-top vial, in packages of 25.</p></td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">PRX22930</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">63323-229-95</p></td>
<td class="Botrule Lrule Rrule Toprule" valign="top"><p class="First">Protamine Sulfate Injection, USP, 250 mg (10 mg/mL, 25 mL) in a single dose flip-top vial, packaged individually.</p></td>
</tr>
</tbody></table>
<p class="First">Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].  Do not permit to freeze.</p>
<p><span class="Bold"><span class="Emphasis">CAUTION: The total dose of protamine sulfate contained in product No. PRX22930 (250 mg in 25 mL) is 5 times greater than in product No. PRX22905 (50 mg in 5 mL).</span></span></p>
<p><span class="Bold"><span class="Emphasis">The large size 25 mL vials are designed for antiheparin treatment only when large doses of heparin have been given during surgery and are to be neutralized by large doses of protamine sulfate after surgical procedures.</span></span></p>
<p>PREMIERPro™Rx is a trademark of Premier, Inc., used under license.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="b82e94ce-5ef7-44a3-8ab6-4dca666433c3"></a><a name="section-12"></a><p></p>
<h1></h1>
<p class="First">Manufactured by:</p>
<p><span class="Bold"><span class="Emphasis">Fresenius Kabi USA, LLC</span></span></p>
<p>Lake Zurich, IL 60047</p>
<p> </p>
<p>451369</p>
<p>Issued: November 2013</p>
<p> </p>
<p><img alt="prx-logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8df0a819-9e1a-44ce-97a6-3ea82c867d44&amp;name=protamine-sulfate-injection-usp-figure-1-prxlogo.jpg"> </p>
<p> </p>
<p> </p>
<p> </p>
<p> </p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="bacbc5e8-6ab1-4a4b-ad67-296360246a03"></a><a name="section-13"></a><p></p>
<h1></h1>
<p class="First"><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Protamine 25 mL Single Dose Vial Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-229-95</p>
<p>PRX22930</p>
<p><span class="Bold"><span class="Emphasis">Protamine Sulfate Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">250 mg/25 mL (10 mg/mL)</span></span></p>
<p>For IV Use Only</p>
<p><span class="Bold"><span class="Emphasis">25 mL</span></span> Single Dose Vial </p>
<p>Rx only</p>
<p><img alt="prx22930-vial" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8df0a819-9e1a-44ce-97a6-3ea82c867d44&amp;name=protamine-sulfate-injection-usp-figure-2-prx22930-vial.jpg"> </p>
<p> </p>
<p><span class="Bold"><span class="Emphasis">PACKAGE LABEL - PRINCIPAL DISPLAY - Protamine 25 mL Single Dose Vial Label</span></span></p>
<p><span class="Bold"><span class="Emphasis">NDC</span></span> 63323-229-95</p>
<p>PRX22930</p>
<p><span class="Bold"><span class="Emphasis">Protamine Sulfate Injection, USP</span></span></p>
<p><span class="Bold"><span class="Emphasis">250 mg/25 mL (10 mg/mL)</span></span></p>
<p>For IV Use Only</p>
<p><span class="Bold"><span class="Emphasis">25 mL</span></span> Single Dose Vial </p>
<p>Rx only</p>
<p> </p>
<p><img alt="prx22930-box" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=8df0a819-9e1a-44ce-97a6-3ea82c867d44&amp;name=protamine-sulfate-injection-usp-figure-3-prx22930-box.jpg"> </p>
<p> </p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>PROTAMINE SULFATE 		
					</strong><br><span class="contentTableReg">protamine sulfate injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:63323-229</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PROTAMINE SULFATE</strong> (PROTAMINE) </td>
<td class="formItem">PROTAMINE SULFATE</td>
<td class="formItem">10 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem">9 mg  in 1 mL</td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SULFURIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM PHOSPHATE, DIBASIC</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:63323-229-94</td>
<td class="formItem">25  in 1 TRAY</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">5 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:63323-229-95</td>
<td class="formItem">1  in 1 BOX</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">25 mL in 1 VIAL, SINGLE-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA089454</td>
<td class="formItem">10/18/2000</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Fresenius Kabi USA, LLC
							(608775388)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Fresenius Kabi USA, LLC</td>
<td class="formItem"></td>
<td class="formItem">023648251</td>
<td class="formItem">MANUFACTURE(63323-229)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 6/2014<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>75e45044-0fca-46c6-94d3-ca8907815ed1</div>
<div>Set id: 8df0a819-9e1a-44ce-97a6-3ea82c867d44</div>
<div>Version: 1</div>
<div>Effective Time: 20140630</div>
</div>
</div> <div class="DistributorName">Fresenius Kabi USA, LLC</div></p>
</body></html>
